Yıl: 2022 Cilt: 52 Sayı: 5 Sayfa Aralığı: 1697 - 1703 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5512 İndeks Tarihi: 27-12-2022

Performance of indirect immunofluorescence test and immunoblot tests in the evaluation of antinuclear and antimitochondrial antibodies

Öz:
Background/aim: Antinuclear antibodies (ANA) and antimitochondrial antibodies (AMA) have essential markers for the diagnosis of autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). These autoantibodies are detecting different laboratory methods. In this study, we studied the diagnostic performance of used methods in detecting ANA and AMA. Materials and methods: The autoantibody profiles of patients with AIH and PBC groups were analyzed with the indirect immunofluorescence test (IIF) and liver-specific antigens containing immunoblot test (IB). Results: There were 45 (87%) women in the study group and 8 (53%) women in the control group. The mean age of the patients was 50.5 ± 14.21 years old. The serum ALT and AST levels were higher in AIH, and ALP, GGT, and Ig M were higher in PBC. IIF test results among AIH/PBC groups; there was no difference in overall ANA positivity (p: 0.078). AMA was negative in all patients with AIH but positive in 83.3% of patients with PBC. IB test results among AIH/PBC groups; antibodies against PDGH, LKM-1, and Scl-70 were not observed in any patient with AIH/PBC. Except for M2 (p: 0.001) and M23E (p: 0.007) antibodies, there was no significant difference in antibodies between groups. Out of five PBC patients with negative AMA by IIF method, one was positive for AMA-M2, two were positive anti-gp210, and three were positive anti-M2-3E, but anti-sp100 was negative in all of them by the IB. Conclusions: AIH/PBC has complex associations with different autoantibodies, and some of these antibodies are not readily detected by the IIF test. IB assays with a wide variety of liver-specific antigens may be helpful in the diagnosis (especially in patients with AMA negative PBC) and follow-up in AIH/PBC patients.
Anahtar Kelime: Autoimmune hepatitis primary biliary cholangitis immunofluorescence test immunoblot test

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: Current diagnostic and clinical challenges. World Journal Gastroenterology 2008; 14 (21): 3374-3387. doi: 10.3748/wjg.14.3374
  • 2. Sebode M, Weiler-Normann C, Liwinski T, Schramm C. Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance. Frontiers in immunology 2018; 27; 9:609. doi: 10.3389/fimmu.2018.00609
  • 3. Lohse AW, Chazouilleres O, Dalekos G, Drenth J, Heneghan M et al. European Association for the Study of the Liver, EASL Clinical Practice Guidelines: Autoimmune hepatitis, Journal of Hepatology 2015; 63(4): 971-1004. doi: 10.1016/j. jhep.2015.06.030
  • 4. Liberal R, Mieli-Vergani G, Vergani D. Clinical significance of autoantibodies in autoimmune hepatitis. Journal of Autoimmunity 2013; 46: 17-24. doi: 10.1016/j.jaut.2013.08.001
  • 5. Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty et al. Autoimmune hepatitis in childhood: A 20-year experience. Hepatology 1997; 25 (3): 541-547. doi: 10.1002/ hep.510250308
  • 6. Czaja AJ. Autoantibodies in Autoimmune Liver Disease, Advances in Clinical Chemistry 2005; 40: 127-164. doi: 10.1016/s0065-2423(05)40004-9
  • 7. Vergani D, Alvarez F, Bianchi FB, Cancado EL, Mackay IR et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. Journal of Hepatology 2004; 41 (4): 677-683. doi: 10.1016/j.jhep.2004.08.002
  • 8. Xiang D, Xia Q, Chen D, Feng X, Zhao Y et al. Detection of D-3-phosphoglycerate dehydrogenas autoantibodies in patients with autoimmune hepatitis: Clinical significance evaluation. Hepatology Research 2011; 41 (9): 867-876. doi: 10.1111/j.1872-034X.2011.00839.x
  • 9. Saito H, Takahashi A, Abe K, Okai K, Katsushima F et al. Autoantibodies by line immunoassay in patients with primary biliary cirrhosis. Fukushima Journal of Medical Science 2012; 58 (2): 107-116. doi: 10.5387/fms.58.107
  • 10. Patel D, Egner W, Gleeson D, Wild G, Ward A. Detection of serum M2 anti-mitochondrial antibodies by enzymelinked immunosorbent assay is potentially less specic than by immuno uorescence. Annals of Clinical Biochemistry 2002; 39 (3): 304-307. doi: 10.1258/0004563021902008
  • 11. Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O et al. Primary biliary cirrhosis — autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28 (2): 296-301. doi: 10.1002/ hep.510280203
  • 12. Ozaslan E, Efe C, Ozaslan NG. The diagnosis of antimitochondrial antibody-negative primary biliary cholangitis. Clinics and Research in Hepatology and Gastroenterology 2016; 40 (5): 553-561. doi: 10.1016/j.clinre.2016.06.001
  • 13. Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Annals of the Rheumatic Diseases 2014; 73 (1): 17- 23. doi: 10.1136/annrheumdis-2013-203863
  • 14. Hirschfield GM. Diagnosis of primary biliary cirrhosis. Best practice & research. Clinical gastroenterology 2011; 25 (6): 701-712. doi: 10.1016/j.bpg.2011.10.005
  • 15. Al-Harthy N, Kumagi T. Natural history and management of primary biliary cirrhosis. Hepatic Medicine 2012; 4 (4): 61-71. doi: 10.2147/HMER.S25998
  • 16. Oertelt S, Rieger R, Selmi C, Invernizzi P, Ansari AA et al. A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis. Hepatology 2007; 45 (3): 659-665. doi: 10.1002/hep.21583
  • 17. Hu CJ, Zhang FC, Li YZ, Zhang X. Primary biliary cirrhosis: What do autoantibodies tell us?. World Journal of Gastroenterology 2010; 7; 16 (29): 3616-3629. doi: 10.3748/wjg.v16.i29.3616
  • 18. Schramm C, Herkel J, Beuers U, Kanzler S, Galle PR et al. Pregnancy in autoimmune hepatitis: outcome and risk factors. The American Journal of Gastroenterology 2006; 101 (3): 556- 560. doi: 10.1111/j.1572-0241.2006.00479.x
  • 19. Granito A, Muratori P, Muratori L, Pappas G, Cassani F et al. Antibodies to SSA/Ro-52 kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Alimentary Pharmacology and Therapeutics 2007; 26 (6): 831-838. doi: 10.1111/j.1365-2036.2007.03433.x
  • 20. Muratorı P, Muratorı L, Gershwın ME, Czajas AJ, Pappas G et al. True’ antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? Clinical and Experimental İmmunology 2004; 135 (1): 154-158. doi: 10.1111/j.1365-2249.2004.02332.x
  • 21. Pang SY, Dai YM, Zhang RZ, Chen YH, Peng XF et al. Autoimmune liver disease-related autoantibodies in patients with biliary atresia, World Journal of Gastroenterology 2018; 21; 24 (3): 387-396. doi: 10.3748/wjg.v24.i3.387
  • 22. Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver International 2012; 32 (1): 85-92. doi: 10.1111/j.1478-3231.2011.02502.x
  • 23. Szostecki C, Krippner H, Penner E, Bautz FA. Autoimmune sera recognize a 100 kD nuclear protein antigen (sp-100). Clinical and Experimental İmmunology 1987; 68 (1): 108-116
  • 24. Mytilinaiou MG, Meyer W, Scheper T, Rigopoulou EI, Probst C et al. Diagnostic and clinical utility of antibodies against the nuclear body promyelocyticleukaemia and Sp100 antigens in patients with primary biliary cirrhosis, Clinica Chimica Acta 2012; 16; 413 (15): 1211-1216. doi: 10.1016/j.cca.2012.03.020
  • 25. Milkiewicz P, Buwaneswaran H, Coltescu C, Shums Z, Norman GL et al. Value of autoantibody analysis in the differential diagnosis of chronic cholestatic liver disease. Clinical Gastroenterology and Hepatology 2009; 7 (12): 1355-1360. doi: 10.1016/j.cgh.2009.07.012
  • 26. Lucena JM, Cano MM, Caro JL, Respaldiza N, Alvarez A et al. Comparison of two ELISA assays for anti-Sp100 determination. In: Annals of the New York Academy of Sciences 2007; 1109:203-211. doi: 10.1196/annals.1398.024
  • 27. Worman HJ. Nuclear envelope protein autoantigens in primary biliary cirrhosis. Hepatology Research 2007; 37 (3): 406-411. doi: 10.1111/j.1872-034X.2007.00227.x
  • 28. Gao L, Tian X, Liu B, Zhang F. The value of antinuclear antibodies in primary biliary cirrhosis. Clinical and Experimental Medicine 2008; 8 (1): 9-15. doi: 10.1007/s10238-008-0150-6
  • 29. Bauer A, Habior A. Measurement of gp210 autoantibodies in sera of patients with primary biliary cirrhosis. Journal of Clinical Laboratory Analysis 2007; 21(4):227-231. doi: 10.1002/ jcla.20170
  • 30.Nakamura M, Shimizu-Yoshida Y, Takii Y, Komori A, Yokoyama T et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. Journal of Hepatology 2005; 42 (3): 386-392. doi: 10.1016/j. jhep.2004.11.016
  • 31. Nakamura M, Komori A, Ito M, Kondo H, Aiba Y et al. Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis. Hepatology Research 2007; 37 (3): 412-419. doi: 10.1111/j.1872-034X.2007.00244.x
  • 32. Bauer A, Habior A. Measurement of gp210 autoantibodies in sera of patients with primary biliary cirrhosis. Journal of Clinical Laboratory Analysis 2007; 21 (4): 227-231. doi: 10.1002/ jcla.20170
  • 33. Yoshida K, Furuya S, Osuka S, Mitoma J, Shinoda Y et al. Targeted disruption of the mouse 3-phosphoglycerate dehydrogenase gene cause severe neurodevelopmental defects and results in embryonic lethality. The Journal of Biological Chemistry 2004; 30; 279 (5): 3573-3577. doi: 10.1074/jbc.C300507200
APA ÖZTÜRK Ö, Demirci Dos Santos Duarte S, balaban h, simsek h, Sener B (2022). Performance of indirect immunofluorescence test and immunoblot tests in the evaluation of antinuclear and antimitochondrial antibodies. , 1697 - 1703. 10.55730/1300-0144.5512
Chicago ÖZTÜRK ÖMER,Demirci Dos Santos Duarte Selay,balaban hatice yasemin,simsek halis,Sener Burcin Performance of indirect immunofluorescence test and immunoblot tests in the evaluation of antinuclear and antimitochondrial antibodies. (2022): 1697 - 1703. 10.55730/1300-0144.5512
MLA ÖZTÜRK ÖMER,Demirci Dos Santos Duarte Selay,balaban hatice yasemin,simsek halis,Sener Burcin Performance of indirect immunofluorescence test and immunoblot tests in the evaluation of antinuclear and antimitochondrial antibodies. , 2022, ss.1697 - 1703. 10.55730/1300-0144.5512
AMA ÖZTÜRK Ö,Demirci Dos Santos Duarte S,balaban h,simsek h,Sener B Performance of indirect immunofluorescence test and immunoblot tests in the evaluation of antinuclear and antimitochondrial antibodies. . 2022; 1697 - 1703. 10.55730/1300-0144.5512
Vancouver ÖZTÜRK Ö,Demirci Dos Santos Duarte S,balaban h,simsek h,Sener B Performance of indirect immunofluorescence test and immunoblot tests in the evaluation of antinuclear and antimitochondrial antibodies. . 2022; 1697 - 1703. 10.55730/1300-0144.5512
IEEE ÖZTÜRK Ö,Demirci Dos Santos Duarte S,balaban h,simsek h,Sener B "Performance of indirect immunofluorescence test and immunoblot tests in the evaluation of antinuclear and antimitochondrial antibodies." , ss.1697 - 1703, 2022. 10.55730/1300-0144.5512
ISNAD ÖZTÜRK, ÖMER vd. "Performance of indirect immunofluorescence test and immunoblot tests in the evaluation of antinuclear and antimitochondrial antibodies". (2022), 1697-1703. https://doi.org/10.55730/1300-0144.5512
APA ÖZTÜRK Ö, Demirci Dos Santos Duarte S, balaban h, simsek h, Sener B (2022). Performance of indirect immunofluorescence test and immunoblot tests in the evaluation of antinuclear and antimitochondrial antibodies. Turkish Journal of Medical Sciences, 52(5), 1697 - 1703. 10.55730/1300-0144.5512
Chicago ÖZTÜRK ÖMER,Demirci Dos Santos Duarte Selay,balaban hatice yasemin,simsek halis,Sener Burcin Performance of indirect immunofluorescence test and immunoblot tests in the evaluation of antinuclear and antimitochondrial antibodies. Turkish Journal of Medical Sciences 52, no.5 (2022): 1697 - 1703. 10.55730/1300-0144.5512
MLA ÖZTÜRK ÖMER,Demirci Dos Santos Duarte Selay,balaban hatice yasemin,simsek halis,Sener Burcin Performance of indirect immunofluorescence test and immunoblot tests in the evaluation of antinuclear and antimitochondrial antibodies. Turkish Journal of Medical Sciences, vol.52, no.5, 2022, ss.1697 - 1703. 10.55730/1300-0144.5512
AMA ÖZTÜRK Ö,Demirci Dos Santos Duarte S,balaban h,simsek h,Sener B Performance of indirect immunofluorescence test and immunoblot tests in the evaluation of antinuclear and antimitochondrial antibodies. Turkish Journal of Medical Sciences. 2022; 52(5): 1697 - 1703. 10.55730/1300-0144.5512
Vancouver ÖZTÜRK Ö,Demirci Dos Santos Duarte S,balaban h,simsek h,Sener B Performance of indirect immunofluorescence test and immunoblot tests in the evaluation of antinuclear and antimitochondrial antibodies. Turkish Journal of Medical Sciences. 2022; 52(5): 1697 - 1703. 10.55730/1300-0144.5512
IEEE ÖZTÜRK Ö,Demirci Dos Santos Duarte S,balaban h,simsek h,Sener B "Performance of indirect immunofluorescence test and immunoblot tests in the evaluation of antinuclear and antimitochondrial antibodies." Turkish Journal of Medical Sciences, 52, ss.1697 - 1703, 2022. 10.55730/1300-0144.5512
ISNAD ÖZTÜRK, ÖMER vd. "Performance of indirect immunofluorescence test and immunoblot tests in the evaluation of antinuclear and antimitochondrial antibodies". Turkish Journal of Medical Sciences 52/5 (2022), 1697-1703. https://doi.org/10.55730/1300-0144.5512